Posted by Michael Wonder on 30 Oct 2024
Lilly Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Verzenio (abemaciclib) in expanded early breast cancer indication
29 October 2024 - Eli Lilly Canada is pleased to announce that it received a positive Canada's Drug Agency (CDA-AMC, formally known as CADTH) recommendation for the Verzenio (abemaciclib) expanded indication in early breast cancer for the full intention to treat population.
Subsequently, Lilly and the pan-Canadian Pharmaceutical Alliance successfully concluded the negotiations for Verzenio's expanded indication on 25 October 2024.
